Acetylcholinesterase

Acetylcholinesterase (AChE) is an enzyme whose sole job is to destroy acetylcholine — the neurotransmitter that carries signals across cholinergic synapses. It sits anchored in the synaptic cleft, the narrow gap between two nerve cells, where it cleaves acetylcholine into choline and acetate within microseconds of its release.

That speed is the point. Without rapid breakdown, acetylcholine would accumulate and keep firing the receiving cell indefinitely. AChE acts as the off-switch, keeping cholinergic signalling brief and precise.

The enzyme is found throughout the nervous system — at neuromuscular junctions, in the autonomic nervous system, and across large parts of the brain, including regions involved in memory and attention.

How it works · its role

When a nerve cell releases acetylcholine, the neurotransmitter binds its receptors (muscarinic or nicotinic) and triggers a response. AChE then intercepts it in the cleft, splitting the molecule in two. The choline fragment is taken back up by the releasing neuron and recycled into new acetylcholine.

Inhibiting AChE disrupts this cycle. When the enzyme is blocked — whether by a drug, a toxin, or an insecticide — acetylcholine cannot be cleared. It accumulates in the synapse and continues stimulating receptors for far longer than normal, amplifying and prolonging every cholinergic signal in the body.

Relevance to substances & effects

Several substance classes work directly by inhibiting AChE. Therapeutic acetylcholinesterase inhibitors — donepezil, rivastigmine, galantamine, and related drugs — are prescribed to slow cognitive decline in Alzheimer's disease by boosting acetylcholine availability in brain regions that have lost cholinergic tone.

At the other end of the spectrum, organophosphate compounds (including certain pesticides and military nerve agents such as sarin and VX) are potent, largely irreversible AChE inhibitors. Their toxicity is a direct consequence of runaway cholinergic signalling across both the central and peripheral nervous system.

Some nootropic compounds used recreationally — including huperzine A, a naturally derived AChE inhibitor — are taken with the aim of enhancing working memory and focus, on the basis that preserved acetylcholine improves attentional circuits. The evidence for cognitive benefit in healthy individuals is limited.

Substances that affect nicotinic acetylcholine receptors (nicotine itself, certain dissociatives) interact with the same cholinergic system, though through a different mechanism — receptor binding rather than enzyme inhibition.

Clinical · risk note

Excessive AChE inhibition triggers a cholinergic crisis: a syndrome caused by uncontrolled accumulation of acetylcholine across the body. Symptoms include profuse sweating, excessive secretions, slowed heart rate, muscle cramps, and in severe cases seizures, respiratory failure, and loss of consciousness.

The risk is highest with organophosphate exposure — accidental poisoning or deliberate use as a weapon — but can also arise from therapeutic overdose or stacking multiple cholinergic compounds. The antidote in acute poisoning is atropine, which blocks muscarinic acetylcholine receptors and counteracts the excess stimulation. Severe cases are a medical emergency.